Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
US7943607B2 · kind B2 · utility
0Cited by
51References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 23, 2006 |
| Grant date | May 17, 2011 |
| Priority date | — |
| Expiry date | Aug 14, 2027 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D419/12
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Compounds of formula (I), wherein R1, R4, HET-1 and HET-2 are as described in the specification, and their salts and pro-drugs, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes. Processes for preparing compounds of formula (I) are also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.